Lenka Reismullerová, Michaela Grossová, Jozef Války, Viera Belušáková
Aromatase inhibitors were originally developed for the treatment of advanced breast cancer in postmenopausal women.
Letrozole was first introduced as a potential ovulation induction drug almost a decade back. Large number of
studies has been published using letrozole for ovulation induction: in polycystic ovary syndrome women, clomiphene
citrate resistant women, for intrauterine insemination and also in various protocols of mild stimulation for in vitro fertilization/
intracytoplasmic sperm injection (IVF/ICSI). For decades, clomiphene citrate a selective oestrogen receptor modulator,
has been a first-choice drug for anovulatory cycles. High ovulation rate (60–90%) make it an attractive therapy
but the pregnancy rate of 10 to 20% is disappointing. Letrozole is an attractive option in ovulation induction and ovarian
stimulation. Letrozole has the potential to be the first-line treatment option for ovulation induction in PCOS women.